Virus manufacturing is key to many therapeutic applications, including viral vectors for gene therapies, viral vaccines, and oncolytic viruses. The demand for those therapies is growing exponentially pushing for new production capacities. However, producing these therapies using traditional technologies face several limitations including, scalability, the need to be flexible enough to accommodate a range of products with ease and manufacturing at reasonable costs. The key to success is to deliver these products in high quantity in a small footprint without compromising on quality. The aim of this presentation will be to explain how intensified, integrated, and automated platform technologies can overcome the main challenges encountered by viral vector manufacturers and respond to the increasing demand for gene therapies. The objective will also be to detail how flexible by design platforms can support multiproduct facilities and result in one system fitting all easily and rapidly deployable.